Report: Covishield produced more antibodies than Covaxin in early study

According to a preliminary study by Coronavirus Vaccine-induced Antibody Titre (COVAT), Covishield vaccine produced more antibodies than Covaxin.

The study involved healthcare workers (HCW) who have received both doses of either of the two vaccines and claimed that Seropositivity rates to anti-spike antibody were significantly higher in Covishield recipients compared to Covaxin after the first dose.

“Amongst the 552 HCW (325 Male, 227 Female), 456 and 96 received the first dose of Covishield and Covaxin respectively. Overall, 79.3 per cent showed seropositivity after the first dose. Responder rate and median (IQR) rise in anti-spike antibody were significantly higher in Covishield vs. Covaxin recipient (86.8 vs. 43.8 per cent; 61.5 vs. 6 AU/ml; both p<0.001),” the study said.

It added, “This ongoing, Pan-India, Cross-sectional, Coronavirus Vaccine-induced Antibody Titre (COVAT) study is being conducted amongst HCW, with or without past history of SARS-CoV-2 infection. SARS-CoV-2 anti-spike binding antibody is being assessed quantitatively at four timepoints between 21 days or more after the first dose to 6 months after the second dose.”